After 10 months of delays, BC Cancer continues to wait for Health Canada approval on a $1M randomized, double-blind, placebo-controlled study on the effects of cannabis on cancer-related symptoms.
- Clinical lead Dr. Pippa Hawley originally expected to be able to begin recruiting patients in June, to deliver results within a year.
- Delays were partly due to Whistler Medical Marijuana, the LP from which researchers had arranged to procure cannabis oil, being acquired by Aurora. Vancouver Sun
A group of more than 10 medical officers and medical directors largely from Canadian LPs wrote to the British Medical Journal to protest an editorial recommending against “prescription of unlicensed cannabis based products to patients on the NHS.”
University of British Columbia researchers published a study charting the structures and chemical outputs of cannabis trichomes.
- Rising MED prices are forcing some patients to buy unregulated product on the illicit market.